- Home
- BRT vs EDIT Comparison
BRT vs EDIT Comparison
Compare BRT & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRT
- EDIT
- Stock Information
- Founded
- BRT 1972
- EDIT 2013
- Country
- BRT United States
- EDIT United States
- Employees
- BRT N/A
- EDIT N/A
- Industry
- BRT Real Estate Investment Trusts
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRT Real Estate
- EDIT Health Care
- Exchange
- BRT Nasdaq
- EDIT Nasdaq
- Market Cap
- BRT 288.5M
- EDIT 241.9M
- IPO Year
- BRT N/A
- EDIT 2016
- Fundamental
- Price
- BRT $16.47
- EDIT $3.00
- Analyst Decision
- BRT Strong Buy
- EDIT Buy
- Analyst Count
- BRT 1
- EDIT 12
- Target Price
- BRT $21.00
- EDIT $5.40
- AVG Volume (30 Days)
- BRT 25.0K
- EDIT 1.4M
- Earning Date
- BRT 11-06-2025
- EDIT 11-03-2025
- Dividend Yield
- BRT 6.06%
- EDIT N/A
- EPS Growth
- BRT N/A
- EDIT N/A
- EPS
- BRT N/A
- EDIT N/A
- Revenue
- BRT $98,407,000.00
- EDIT $38,901,000.00
- Revenue This Year
- BRT N/A
- EDIT N/A
- Revenue Next Year
- BRT $4.51
- EDIT N/A
- P/E Ratio
- BRT N/A
- EDIT N/A
- Revenue Growth
- BRT 2.46
- EDIT N/A
- 52 Week Low
- BRT $14.17
- EDIT $0.91
- 52 Week High
- BRT $20.22
- EDIT $4.12
- Technical
- Relative Strength Index (RSI)
- BRT 62.89
- EDIT 60.05
- Support Level
- BRT $16.01
- EDIT $2.54
- Resistance Level
- BRT $16.69
- EDIT $2.84
- Average True Range (ATR)
- BRT 0.42
- EDIT 0.20
- MACD
- BRT 0.05
- EDIT 0.03
- Stochastic Oscillator
- BRT 82.95
- EDIT 89.27
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.